DocWire News Editors

DocwireNews

Chicago&mdash;The current standard of care in patients with very high risk prostate cancer is radiotherapy and 18 to 28 months of androgen deprivation therapy (ADT); however, according to Sean Matthew McBride, MD, and colleagues, biochemical failure is frequent. Dr. McBride et al. designed a single arm, phase 2 trial to test the hypothesis that stereotactic, hypofractionated radiotherapy (SBRT) delivered with a total of 6 months of apalutamide, abiraterone, and leuprolide will result in a superior 3-year rate of biochemical control in that patient population compared with 42 to 48 conventionally fractionated radiation therapy and long-term ADT. The researchers defined high risk of prostate cancer as Gleason score 9-10 or two high risk features or more than four Gleason 8 cores.The trial is designed to determine the efficacy of anti-androgen therapy combined with SBRT in very high-risk prostate cancer. The researchers described study protocol during a poster session at the ASCO 2018 Annual Meeting in a poster titled Apalutamide + Abiraterone + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer (PCa).The primary end point is the proportion of patients with biochemical failure, defined as nadir plus 2 at 36 months post ADT completion. Eligible patients will receive 6 months of leuprolide, abiraterone, and apalutamide 3 months prior to SBRT; ADT will continue for 3 months post-SBRT. Patient assessment will occur every 4 weeks (&plusmn;1 week) (cycle=28 days) throughout the study treatment period as well as at least once during SBRT.Prior to the initiation of SBRT, patients will be required to undergo a prostate biopsy, and two additional biopsies (one at 24 months and, if applicable, upon metastatic progression) will be performed. Partial exome analyses will be performed on all biopsies; additional correlatives include circulating tumor cell evaluation and cell-free DNA measurements pre- and post-treatment.Should toxicities exceed historical controls, interim analysis will ensure early termination. The study plans to enroll 58 patients; 32 have been enrolled to date. The trial is open at five sites and managed by the Prostate Cancer Clinical Consortium and is funded by Janssen.Clinical trial information: NCT02772588Source: McBride SM, Zelefsky MJ, Spratt DE, et al. Apalutamide + abiraterone + leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa). Abstract of a poster presented at the American Society of Clinical Oncology 2018 Annual Meeting, June 2, 2018, Chicago, Illinois.

BMI Modifies the Relationship Between Glycemic Status and Asthma Severity in Children

Asthma

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Latest News

Study Protocol to Assess Efficacy of Anti-Androgen Therapy plus SBRT in High-Risk Patients

ASCO 2018

Chicago—The current standard of care in patients with very high risk prostate cancer is radiotherapy and 18 to 28 months of androgen deprivation therapy (ADT); however, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe